サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1625398

非アルコール性脂肪肝炎治療市場、規模、シェア、動向、産業分析レポート：薬剤別、疾患ステージ別、流通チャネル別、地域別 - 市場予測、2025年～2034年

Non-alcoholic Steatohepatitis Treatment Market Size, Share, Trends, Industry Analysis Report: By Drug, Disease Stage, Distribution Channel, and Region - Market Forecast, 2025-2034

出版日
ページ情報
英文 128 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
非アルコール性脂肪肝炎治療市場、規模、シェア、動向、産業分析レポート：薬剤別、疾患ステージ別、流通チャネル別、地域別 - 市場予測、2025年～2034年
出版日: 2024年12月01日
発行: Polaris Market Research
ページ情報: 英文 128 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、非アルコール性脂肪肝炎（NASH）治療市場規模は2034年までに909億7,000万米ドルに達する見込みです。このレポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

非アルコール性脂肪肝炎（NASH）治療市場の成長は、NASHの開拓に強く関連する肥満、2型糖尿病、メタボリックシンドロームなどの危険因子の有病率の上昇に起因しています。世界中でNASHの有病率が上昇していることから、製薬企業にとって十分な市場機会が創出されると期待されています。

NASH治療市場は、肝炎、線維化、インスリン抵抗性を含むNASHの複雑な病態生理を標的とした研究努力と革新的な治療法の増加により、力強い成長軌道に乗ると予想されます。NASH治療の市場規模は、北米、欧州、アジア太平洋などの地域を中心に世界のNASH罹患率の上昇が続いていることから、拡大傾向にあります。

非アルコール性脂肪肝炎治療市場の見通しは楽観的で、オベチコール酸（OCA）、セマグルチド、ラニフィブラノール、ビタミンEなど、臨床試験を進め、規制当局の承認を得た治療薬の数が増加しています。ヘルスケアへのアクセスの拡大、NASHに関する意識の高まり、肝臓疾患への関心の高まりが、NASH治療に対する需要の高まりに寄与しています。さらに、特に先進諸国では高齢化が進んでおり、革新的な治療法の必要性が高まっています。診断と治療オプションの進歩は、ヘルスケア業界内の利害関係者に大きな成長の可能性と機会を提供し、大幅な拡大を促進するように設定されています。

非アルコール性脂肪肝炎治療市場レポートハイライト

薬剤別では、2024年にビタミンEとピオグリタゾンのセグメントが非アルコール性脂肪肝炎（NASH）治療市場収益の最大シェアを占めたが、これはNASH患者の肝炎抑制とインスリン感受性改善に対する有効性が確立されているためです。

流通チャネルに基づく小売・専門薬局システム分野は、アクセスしやすく、NASH治療のための専門的な薬剤や患者サポートを提供できることから、予測期間中に最も高いCAGRを記録すると予想されます。

2024年には、北米が非アルコール性脂肪肝炎治療市場シェアを独占したが、これは肥満と2型糖尿病の有病率の高さに加え、強力なヘルスケアインフラと肝疾患調査への多額の投資によるものです。

アジア太平洋市場は、ヘルスケア支出の増加と肝疾患管理に対する意識の高まりにより、予測期間中に大きな成長が見込まれています。

世界の主な市場参入企業は、Intercept Pharmaceuticals, Inc.; Galmed Pharmaceuticals Ltd; Inventiva; AbbVie Inc.; Galectin Therapeutics Inc.; Madrigal Pharmaceuticals Inc (Madrigal); NGM Biopharmaceuticals, Inc.; Novo Nordisk A/S; The Bristol-Myers Squibb Company; and Gilead Sciences, Inc.などです。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の非アルコール性脂肪肝炎治療市場の洞察

  • 市場スナップショット
  • 非アルコール性脂肪肝炎治療市場力学
    • 促進要因と機会
      • 高齢化人口の増加
      • 2型糖尿病の発症率の上昇
    • 抑制要因と課題
      • 高額な治療費
  • PESTEL分析
  • 非アルコール性脂肪肝炎治療市場の動向
  • バリューチェーン分析
  • COVID-19の影響分析

第5章 世界の非アルコール性脂肪肝炎治療市場：薬剤別

  • 主な調査結果
  • イントロダクション
  • ビタミンEとピオグリタゾン
  • オベチコール酸（OCA）
  • ラニフィブラノール
  • セマグルチド
  • レスメチロム
  • アラムチョル
  • セニクリビロック
  • その他の薬剤

第6章 世界の非アルコール性脂肪肝炎治療市場：疾患ステージ別

  • 主な調査結果
  • イントロダクション
  • NASHステージF0
  • NASHステージF1
  • NASHステージF2
  • NASHステージF3
  • NASHステージF4

第7章 世界の非アルコール性脂肪肝炎治療市場：流通チャネル別

  • 主な調査結果
  • イントロダクション
  • 病院薬局
  • 小売および専門薬局
  • その他の薬局

第8章 世界の非アルコール性脂肪肝炎治療市場：地域別

  • 主な調査結果
  • イントロダクション
    • 非アルコール性脂肪肝炎治療市場評価：地域別、2020-2034年
  • 北米
    • 北米：薬剤別、2020-2034年
    • 北米：疾患ステージ別、2020-2034年
    • 北米：流通チャネル別、2020-2034年
    • 米国
    • カナダ
  • 欧州
    • 欧州：薬剤別、2020-2034年
    • 欧州：疾患ステージ別、2020-2034年
    • 欧州：流通チャネル別、2020-2034年
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • オランダ
    • ロシア
    • その他欧州
  • アジア太平洋
    • アジア太平洋地域：薬剤別、2020-2034年
    • アジア太平洋地域：疾患ステージ別、2020-2034年
    • アジア太平洋地域：流通チャネル別、2020-2034年
    • 中国
    • インド
    • マレーシア
    • 日本
    • インドネシア
    • 韓国
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ
    • 中東・アフリカ：薬剤別、2020-2034年
    • 中東・アフリカ：疾患ステージ別、2020-2034年
    • 中東・アフリカ：流通チャネル別、2020-2034年
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東とアフリカ
  • ラテンアメリカ
    • ラテンアメリカ：薬剤別、2020-2034年
    • ラテンアメリカ：疾患ステージ別、2020-2034年
    • ラテンアメリカ：流通チャネル別、2020-2034年
    • メキシコ
    • ブラジル
    • アルゼンチン
    • その他ラテンアメリカ

第9章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第10章 企業プロファイル

  • Intercept Pharmaceuticals, Inc.
  • Galmed Pharmaceuticals Ltd
  • Inventiva
  • AbbVie Inc.
  • Galectin Therapeutics Inc.
  • Madrigal Pharmaceuticals Inc.（Madrigal）
  • NGM Biopharmaceuticals, Inc.
  • Novo Nordisk A/S
  • The Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
図表

List of Tables:

Table 1 Global Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 2 Global Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 3 Global Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 4 North America: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 5 North America: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 6 North America: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 7 U.S.: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 8 U.S.: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 9 U.S.: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 10 Canada: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 11 Canada: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 12 Canada: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 13 Europe: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 14 Europe: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 15 Europe: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 16 UK: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 17 UK: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 18 UK: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 19 France: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 20 France: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 21 France: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 22 Germany: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 23 Germany: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 24 Germany: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 25 Italy: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 26 Italy: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 27 Italy: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 28 Spain: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 29 Spain: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 30 Spain: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 31 Netherlands: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 32 Netherlands: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 33 Netherlands: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 34 Russia: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 35 Russia: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 36 Russia: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 37 Rest of Europe: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 38 Rest of Europe: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 39 Rest of Europe: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 40 Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 41 Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 42 Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 43 China: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 44 China: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 45 China: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 46 India: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 47 India: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 48 India: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 49 Malaysia: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 50 Malaysia: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 51 Malaysia: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 52 Japan: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 53 Japan: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 54 Japan: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 55 Indonesia: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 56 Indonesia: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 57 Indonesia: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 58 South Korea: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 59 South Korea: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 60 South Korea: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 61 Australia: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 62 Australia: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 63 Australia: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 64 Rest of Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 65 Rest of Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 66 Rest of Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 67 Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 68 Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 69 Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 70 Saudi Arabia: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 71 Saudi Arabia: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 72 Saudi Arabia: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 73 UAE: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 74 UAE: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 75 UAE: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 76 Israel: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 77 Israel: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 78 Israel: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 79 South Africa: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 80 South Africa: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 81 South Africa: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 82 Rest of Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 83 Rest of Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 84 Rest of Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 85 Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 86 Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 87 Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 88 Mexico: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 89 Mexico: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 90 Mexico: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 91 Brazil: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 92 Brazil: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 93 Brazil: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 94 Argentina: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 95 Argentina: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 96 Argentina: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

Table 97 Rest of Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)

Table 98 Rest of Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)

Table 99 Rest of Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

List of Figures:

Figure 1. Global Non-alcoholic Steatohepatitis Treatment Market, 2020-2034 (USD Billion)

Figure 2. Integrated Ecosystem

Figure 3. Research Methodology: Top-Down & Bottom-Up Price

Figure 4. Market by Geography

Figure 5. Porter's Five Forces

Figure 6. Market by Drug

Figure 7. Global Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2024 & 2034 (USD Billion)

Figure 8. Market by Disease Stage

Figure 9. Global Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2024 & 2034 (USD Billion)

Figure 10. Market by Distribution Channel

Figure 11. Global Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2024 & 2034 (USD Billion)

目次
Product Code: PM5283

The non-alcoholic steatohepatitis treatment market size is expected to reach USD 90.97 billion by 2034, according to a new study by Polaris Market Research. The report "Non-alcoholic Steatohepatitis Treatment Market Share, Size, Trends, Industry Analysis Report: By Drug, Disease Stage, Distribution Channel (Hospital Pharmacies, Retail and Specialty Pharmacies, and Other Pharmacies), and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa); Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The non-alcoholic steatohepatitis (NASH) treatment market growth is attributed to the rising prevalence of risk factors such as obesity, type 2 diabetes, and metabolic syndrome, strongly linked to the development of NASH. The rising prevalence of NASH across the world is expected to create ample market opportunities for pharmaceutical companies.

The NASH treatment market is expected to experience a robust growth trajectory, increasing research efforts and innovative therapies targeting the complex pathophysiology of NASH, including liver inflammation, fibrosis, and insulin resistance. The market size for NASH treatments is expanding, with the global incidence of NASH continuing to rise, particularly in regions such as North America, Europe, and Asia Pacific.

The non-alcoholic steatohepatitis treatment market outlook is optimistic, with a growing number of drugs, including Obeticholic Acid (OCA), Semaglutide, Lanifibranor, and Vitamin E, advancing through clinical trials and receiving regulatory approvals. The expansion of healthcare access, increased awareness about NASH, and the growing focus on liver diseases contribute to the rising demand for NASH treatments. Moreover, the aging population, especially in developed countries, accelerates the need for innovative therapies. Advancements in diagnostics and treatment options are set to drive significant expansion, offering considerable growth potential and opportunities for stakeholders within the healthcare industry.

Non-alcoholic Steatohepatitis Treatment Market Report Highlights

In terms of drug, in 2024, the vitamin E and pioglitazone segment accounted for the largest share of the non-alcoholic steatohepatitis (NASH) treatment market revenue due to its well-established efficacy in reducing liver inflammation and improving insulin sensitivity in NASH patients.

The retail and specialty pharmacies systems segment, based on distribution channel, is expected to witness the highest CAGR during the forecast period due to its accessibility and ability to provide specialized medications and patient support for NASH treatment.

In 2024, North America dominated the non-alcoholic steatohepatitis treatment market share due to the high prevalence of obesity and type 2 diabetes, coupled with strong healthcare infrastructure and substantial investment in liver disease research.

The Asia Pacific market is expected to witness significant growth during the forecast period due to increasing healthcare expenditure and greater awareness of liver disease management.

A few global key market players are Intercept Pharmaceuticals, Inc.; Galmed Pharmaceuticals Ltd; Inventiva; AbbVie Inc.; Galectin Therapeutics Inc.; Madrigal Pharmaceuticals Inc (Madrigal); NGM Biopharmaceuticals, Inc.; Novo Nordisk A/S; The Bristol-Myers Squibb Company; and Gilead Sciences, Inc.

Polaris Market Research has segmented the non-alcoholic steatohepatitis treatment market report on the basis of drug, disease stage, distribution channel, and region:

By Drug Outlook (Revenue, USD Billion; 2020-2034)

  • Vitamin E and Pioglitazone
  • Obeticholic Acid (OCA)
  • Lanifibranor
  • Semaglutide
  • Resmetirom
  • Aramchol
  • Cenicriviroc
  • Other Drugs

By Disease Stage Outlook (Revenue, USD Billion; 2020-2034)

  • NASH Stage F0
  • NASH Stage F1
  • NASH Stage F2
  • NASH Stage F3
  • NASH Stage F4

By Distribution Channel Outlook (Revenue, USD Billion; 2020-2034)

  • Hospital Pharmacies
  • Retail and Specialty Pharmacies
  • Other Pharmacies

By Regional Outlook (Revenue, USD Billion; 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Rest of Asia Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Non-alcoholic Steatohepatitis Treatment Market Insights

  • 4.1. Non-alcoholic Steatohepatitis Treatment Market - Market Snapshot
  • 4.2. Non-alcoholic Steatohepatitis Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Aging Population
      • 4.2.1.2. Rising Incidence of Type 2 Diabetes
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High Treatment Costs
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Non-alcoholic Steatohepatitis Treatment Market Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Non-alcoholic Steatohepatitis Treatment Market, by Drug

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
  • 5.3. Vitamin E and Pioglitazone
    • 5.3.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Vitamin E and Pioglitazone, by Region, 2020-2034 (USD Billion)
  • 5.4. Obeticholic Acid (OCA)
    • 5.4.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Obeticholic Acid (OCA), by Region, 2020-2034 (USD Billion)
  • 5.5. Lanifibranor
    • 5.5.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Lanifibranor, by Region, 2020-2034 (USD Billion)
  • 5.6. Semaglutide
    • 5.6.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Semaglutide, by Region, 2020-2034 (USD Billion)
  • 5.7. Resmetirom
    • 5.7.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Resmetirom, by Region, 2020-2034 (USD Billion)
  • 5.8. Aramchol
    • 5.8.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Aramchol, by Region, 2020-2034 (USD Billion)
  • 5.9. Cenicriviroc
    • 5.9.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Cenicriviroc, by Region, 2020-2034 (USD Billion)
  • 5.10. Other Drugs
    • 5.10.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Other Drugs, by Region, 2020-2034 (USD Billion)

6. Global Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
  • 6.3. NASH Stage F0
    • 6.3.1. Global Non-alcoholic Steatohepatitis Treatment Market, by NASH Stage F0, by Region, 2020-2034 (USD Billion)
  • 6.4. NASH Stage F1
    • 6.4.1. Global Non-alcoholic Steatohepatitis Treatment Market, by NASH Stage F1, by Region, 2020-2034 (USD Billion)
  • 6.5. NASH Stage F2
    • 6.5.1. Global Non-alcoholic Steatohepatitis Treatment Market, by NASH Stage F2, by Region, 2020-2034 (USD Billion)
  • 6.6. NASH Stage F3
    • 6.6.1. Global Non-alcoholic Steatohepatitis Treatment Market, by NASH Stage F3, by Region, 2020-2034 (USD Billion)
  • 6.7. NASH Stage F4
    • 6.7.1. Global Non-alcoholic Steatohepatitis Treatment Market, by NASH Stage F4, by Region, 2020-2034 (USD Billion)

7. Global Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Hospital Pharmacies, by Region, 2020-2034 (USD Billion)
  • 7.4. Retail and Specialty Pharmacies
    • 7.4.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Retail and Specialty Pharmacies, by Region, 2020-2034 (USD Billion)
  • 7.5. Other Pharmacies
    • 7.5.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Other Pharmacies, by Region, 2020-2034 (USD Billion)

8. Global Non-alcoholic Steatohepatitis Treatment Market, by Geography

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Non-alcoholic Steatohepatitis Treatment Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 8.3. Non-alcoholic Steatohepatitis Treatment Market - North America
    • 8.3.1. North America: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
    • 8.3.2. North America: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
    • 8.3.3. North America: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.3.4. Non-alcoholic Steatohepatitis Treatment Market - U.S.
      • 8.3.4.1. U.S.: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.3.4.2. U.S.: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.3.4.3. U.S.: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.3.5. Non-alcoholic Steatohepatitis Treatment Market - Canada
      • 8.3.5.1. Canada: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.3.5.2. Canada: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.3.5.3. Canada: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.4. Non-alcoholic Steatohepatitis Treatment Market - Europe
    • 8.4.1. Europe: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
    • 8.4.2. Europe: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
    • 8.4.3. Europe: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.4. Non-alcoholic Steatohepatitis Treatment Market - UK
      • 8.4.4.1. UK: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.4.4.2. UK: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.4.4.3. UK: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.5. Non-alcoholic Steatohepatitis Treatment Market - France
      • 8.4.5.1. France: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.4.5.2. France: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.4.5.3. France: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.6. Non-alcoholic Steatohepatitis Treatment Market - Germany
      • 8.4.6.1. Germany: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.4.6.2. Germany: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.4.6.3. Germany: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.7. Non-alcoholic Steatohepatitis Treatment Market - Italy
      • 8.4.7.1. Italy: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.4.7.2. Italy: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.4.7.3. Italy: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.8. Non-alcoholic Steatohepatitis Treatment Market - Spain
      • 8.4.8.1. Spain: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.4.8.2. Spain: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.4.8.3. Spain: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.9. Non-alcoholic Steatohepatitis Treatment Market - Netherlands
      • 8.4.9.1. Netherlands: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.4.9.2. Netherlands: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.4.9.3. Netherlands: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.10. Non-alcoholic Steatohepatitis Treatment Market - Russia
      • 8.4.10.1. Russia: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.4.10.2. Russia: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.4.10.3. Russia: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.11. Non-alcoholic Steatohepatitis Treatment Market - Rest of Europe
      • 8.4.11.1. Rest of Europe: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.4.11.2. Rest of Europe: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.4.11.3. Rest of Europe: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.5. Non-alcoholic Steatohepatitis Treatment Market - Asia Pacific
    • 8.5.1. Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
    • 8.5.2. Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
    • 8.5.3. Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.4. Non-alcoholic Steatohepatitis Treatment Market - China
      • 8.5.4.1. China: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.5.4.2. China: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.5.4.3. China: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.5. Non-alcoholic Steatohepatitis Treatment Market - India
      • 8.5.5.1. India: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.5.5.2. India: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.5.5.3. India: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.6. Non-alcoholic Steatohepatitis Treatment Market - Malaysia
      • 8.5.6.1. Malaysia: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.5.6.2. Malaysia: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.5.6.3. Malaysia: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.7. Non-alcoholic Steatohepatitis Treatment Market - Japan
      • 8.5.7.1. Japan: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.5.7.2. Japan: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.5.7.3. Japan: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.8. Non-alcoholic Steatohepatitis Treatment Market - Indonesia
      • 8.5.8.1. Indonesia: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.5.8.2. Indonesia: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.5.8.3. Indonesia: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.9. Non-alcoholic Steatohepatitis Treatment Market - South Korea
      • 8.5.9.1. South Korea: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.5.9.2. South Korea: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.5.9.3. South Korea: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.10. Non-alcoholic Steatohepatitis Treatment Market - Australia
      • 8.5.10.1. Australia: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.5.10.2. Australia: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.5.10.3. Australia: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.11. Non-alcoholic Steatohepatitis Treatment Market - Rest of Asia Pacific
      • 8.5.11.1. Rest of Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.5.11.2. Rest of Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.5.11.3. Rest of Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.6. Non-alcoholic Steatohepatitis Treatment Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
    • 8.6.2. Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
    • 8.6.3. Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.4. Non-alcoholic Steatohepatitis Treatment Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.6.4.2. Saudi Arabia: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.5. Non-alcoholic Steatohepatitis Treatment Market - UAE
      • 8.6.5.1. UAE: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.6.5.2. UAE: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.6.5.3. UAE: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.6. Non-alcoholic Steatohepatitis Treatment Market - Israel
      • 8.6.6.1. Israel: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.6.6.2. Israel: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.6.6.3. Israel: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.7. Non-alcoholic Steatohepatitis Treatment Market - South Africa
      • 8.6.7.1. South Africa: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.6.7.2. South Africa: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.6.7.3. South Africa: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.8. Non-alcoholic Steatohepatitis Treatment Market - Rest of Middle East & Africa
      • 8.6.8.1. Rest of Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.6.8.2. Rest of Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.6.8.3. Rest of Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.7. Non-alcoholic Steatohepatitis Treatment Market - Latin America
    • 8.7.1. Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
    • 8.7.2. Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
    • 8.7.3. Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.4. Non-alcoholic Steatohepatitis Treatment Market - Mexico
      • 8.7.4.1. Mexico: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.7.4.2. Mexico: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.7.4.3. Mexico: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.5. Non-alcoholic Steatohepatitis Treatment Market - Brazil
      • 8.7.5.1. Brazil: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.7.5.2. Brazil: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.7.5.3. Brazil: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.6. Non-alcoholic Steatohepatitis Treatment Market - Argentina
      • 8.7.6.1. Argentina: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.7.6.2. Argentina: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.7.6.3. Argentina: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.7. Non-alcoholic Steatohepatitis Treatment Market - Rest of Latin America
      • 8.7.7.1. Rest of Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.7.7.2. Rest of Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.7.7.3. Rest of Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Intercept Pharmaceuticals, Inc.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Galmed Pharmaceuticals Ltd
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Inventiva
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. AbbVie Inc.
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Galectin Therapeutics Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Madrigal Pharmaceuticals Inc. (Madrigal)
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. NGM Biopharmaceuticals, Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Novo Nordisk A/S
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. The Bristol-Myers Squibb Company
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Gilead Sciences, Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development